CN102311449A - 棉酚衍生物在制备抗肿瘤药物中的应用 - Google Patents
棉酚衍生物在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN102311449A CN102311449A CN2010102193119A CN201010219311A CN102311449A CN 102311449 A CN102311449 A CN 102311449A CN 2010102193119 A CN2010102193119 A CN 2010102193119A CN 201010219311 A CN201010219311 A CN 201010219311A CN 102311449 A CN102311449 A CN 102311449A
- Authority
- CN
- China
- Prior art keywords
- compound
- cell
- gossypol
- bcl
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/10—Modification of an amino radical directly attached in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/14—Preparation of salts
- C07D499/16—Preparation of salts of alkali or alkaline earth metals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102193119A CN102311449B (zh) | 2010-07-02 | 2010-07-02 | 棉酚衍生物在制备抗肿瘤药物中的应用 |
PCT/CN2011/076482 WO2012000421A1 (zh) | 2010-07-02 | 2011-06-28 | 棉酚衍生物在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102193119A CN102311449B (zh) | 2010-07-02 | 2010-07-02 | 棉酚衍生物在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102311449A true CN102311449A (zh) | 2012-01-11 |
CN102311449B CN102311449B (zh) | 2013-11-20 |
Family
ID=45401394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102193119A Expired - Fee Related CN102311449B (zh) | 2010-07-02 | 2010-07-02 | 棉酚衍生物在制备抗肿瘤药物中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102311449B (zh) |
WO (1) | WO2012000421A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102690326A (zh) * | 2012-05-29 | 2012-09-26 | 武汉大学 | 具有抗艾滋病毒活性的棉酚新衍生物及其制备 |
CN103265560A (zh) * | 2013-05-17 | 2013-08-28 | 上海中科高等研究院 | 棉酚/棉酮衍生物及其制备方法和抗肿瘤药物中的应用 |
CN104817472A (zh) * | 2015-03-25 | 2015-08-05 | 武汉大学 | 一种新型棉酚衍生物及其制备方法和抗肿瘤应用 |
CN105503627A (zh) * | 2015-12-10 | 2016-04-20 | 武汉大学 | 一种新型棉酚希夫碱衍生物及其制备方法与应用 |
CN107382944A (zh) * | 2017-03-27 | 2017-11-24 | 陕西科技大学 | 一类具有抗肿瘤活性的香豆素棉酚衍生物及其合成方法 |
CN107382866A (zh) * | 2017-03-27 | 2017-11-24 | 陕西科技大学 | 一种具有抗肿瘤活性的棉酚依达拉奉缩合物及其合成方法 |
CN107417580A (zh) * | 2017-09-12 | 2017-12-01 | 陕西科技大学 | 一类具有抗肿瘤活性的棉酚‑l‑精氨酸席夫碱类化合物及其合成方法 |
CN107573318A (zh) * | 2017-09-12 | 2018-01-12 | 陕西科技大学 | 一种具抗肿瘤活性的新型棉酚席夫碱类衍生物及其合成方法 |
CN113214066A (zh) * | 2020-02-04 | 2021-08-06 | 中国医学科学院药物研究所 | 棉酚晶ii型物质及制备方法和其组合物与用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1887838A (zh) * | 2006-07-14 | 2007-01-03 | 中国科学院上海有机化学研究所 | 酸和丙酮水溶液一步法制备酸性棉酚衍生物的方法 |
CN1911215A (zh) * | 2003-06-11 | 2007-02-14 | 中国科学院动物研究所 | 棉酚及其衍生物在制备治疗白血病药物中的应用 |
WO2009045410A1 (en) * | 2007-10-01 | 2009-04-09 | Ascenta Therapeutics, Inc. | Process for preparing r-gossypol l-phenylalaninol dienamine |
-
2010
- 2010-07-02 CN CN2010102193119A patent/CN102311449B/zh not_active Expired - Fee Related
-
2011
- 2011-06-28 WO PCT/CN2011/076482 patent/WO2012000421A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911215A (zh) * | 2003-06-11 | 2007-02-14 | 中国科学院动物研究所 | 棉酚及其衍生物在制备治疗白血病药物中的应用 |
CN1887838A (zh) * | 2006-07-14 | 2007-01-03 | 中国科学院上海有机化学研究所 | 酸和丙酮水溶液一步法制备酸性棉酚衍生物的方法 |
WO2009045410A1 (en) * | 2007-10-01 | 2009-04-09 | Ascenta Therapeutics, Inc. | Process for preparing r-gossypol l-phenylalaninol dienamine |
Non-Patent Citations (3)
Title |
---|
JUN WEI ET AL: "Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists", 《CANCER LETTERS》, vol. 273, 31 December 2009 (2009-12-31), pages 107 - 113, XP025685881, DOI: doi:10.1016/j.canlet.2008.07.031 * |
PIOTR PRZYBYLSKI ET AL: "1H- and 13C-NMR, FTIR, UV-VIS,ESI-MS, and PM5 Studies as Well as Emission Properties of a New Schiff Base of Gossypol with 5-Methoxytryptamine and a New Hydrazone of Gossypol with Dansylhydrazine", 《BIOPOLYMERS》, vol. 82, 14 March 2006 (2006-03-14), pages 521 - 535 * |
张献清 等: "新型棉酚衍生物ApoG2对人前列腺癌PC - 3移植瘤生长的抑制", 《现代肿瘤医学》, vol. 18, no. 2, 28 February 2010 (2010-02-28), pages 259 - 263 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102690326A (zh) * | 2012-05-29 | 2012-09-26 | 武汉大学 | 具有抗艾滋病毒活性的棉酚新衍生物及其制备 |
CN103467538A (zh) * | 2012-05-29 | 2013-12-25 | 武汉大学 | 具有抗艾滋病毒活性的棉酚衍生物及其制备方法 |
CN102690326B (zh) * | 2012-05-29 | 2014-04-02 | 武汉大学 | 具有抗艾滋病毒活性的棉酚衍生物及其制备 |
CN103265560A (zh) * | 2013-05-17 | 2013-08-28 | 上海中科高等研究院 | 棉酚/棉酮衍生物及其制备方法和抗肿瘤药物中的应用 |
CN104817472A (zh) * | 2015-03-25 | 2015-08-05 | 武汉大学 | 一种新型棉酚衍生物及其制备方法和抗肿瘤应用 |
CN105503627A (zh) * | 2015-12-10 | 2016-04-20 | 武汉大学 | 一种新型棉酚希夫碱衍生物及其制备方法与应用 |
CN107382944A (zh) * | 2017-03-27 | 2017-11-24 | 陕西科技大学 | 一类具有抗肿瘤活性的香豆素棉酚衍生物及其合成方法 |
CN107382866A (zh) * | 2017-03-27 | 2017-11-24 | 陕西科技大学 | 一种具有抗肿瘤活性的棉酚依达拉奉缩合物及其合成方法 |
CN107417580A (zh) * | 2017-09-12 | 2017-12-01 | 陕西科技大学 | 一类具有抗肿瘤活性的棉酚‑l‑精氨酸席夫碱类化合物及其合成方法 |
CN107573318A (zh) * | 2017-09-12 | 2018-01-12 | 陕西科技大学 | 一种具抗肿瘤活性的新型棉酚席夫碱类衍生物及其合成方法 |
CN113214066A (zh) * | 2020-02-04 | 2021-08-06 | 中国医学科学院药物研究所 | 棉酚晶ii型物质及制备方法和其组合物与用途 |
CN113214066B (zh) * | 2020-02-04 | 2024-05-14 | 中国医学科学院药物研究所 | 棉酚晶ii型物质及制备方法和其组合物与用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2012000421A1 (zh) | 2012-01-05 |
CN102311449B (zh) | 2013-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102311449B (zh) | 棉酚衍生物在制备抗肿瘤药物中的应用 | |
CN103265560A (zh) | 棉酚/棉酮衍生物及其制备方法和抗肿瘤药物中的应用 | |
CA2936012C (en) | Functionalised benzopyran compounds and use thereof | |
US10759803B2 (en) | Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto | |
CN105985323A (zh) | 新型表皮生长因子受体抑制剂及其应用 | |
CN106749089A (zh) | 新型氟代噻唑腙类化合物的制备及其在抗肿瘤药物中的应用 | |
Assali et al. | Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity | |
JP2015501792A (ja) | ベンジリデンベンゾヒドラジドを用いた卵巣がんの治療 | |
CN103965175B (zh) | 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 | |
CN102573833A (zh) | 癌细胞凋亡 | |
CN106748939B (zh) | 一类新型溴酚氨基硫脲类化合物及其制备和药物与用途 | |
CN101429175B (zh) | 一种具有抗肿瘤活性的紫苏醇衍生物及其用途 | |
JP7018191B2 (ja) | 細胞内物質移送システムおよびその利用 | |
JP6404220B2 (ja) | テアニン誘導体とカルボン酸クマリン誘導体との縮合生成物、その中間体、調製方法、及びその使用 | |
CN105541859A (zh) | 二氢呋喃并色满酮衍生物及其制备方法与医药用途 | |
WO2018014368A1 (zh) | 一种水溶性靛红衍生物及其制备方法与应用 | |
CN106749088A (zh) | 一类新型溴酚‑噻唑类化合物及其制备和药物与用途 | |
CN103755695B (zh) | 一种具有抗肿瘤活性的酰胺类化合物及其应用 | |
CN104672213A (zh) | 一种具有抗肿瘤活性的酰胺类化合物及其应用 | |
CN103012394B (zh) | 一种罗丹宁衍生物及其制备方法 | |
CN105061352A (zh) | 芳基哌嗪衍生物ⅲ及其盐、制备方法和用途 | |
JP2014533273A (ja) | 2−アミノ−4H−ナフト[1,2−b]ピラン−3−カルボニトリルを用いた卵巣がんの治療 | |
CN110590778A (zh) | 3,10二对甲氧基苯基6,12二氮杂四高立方烷类化合物及合成方法应用和药物组合物 | |
CN105541696B (zh) | 一种抗肿瘤的化合物及其制备方法和应用 | |
CN106361752A (zh) | 氟哌噻吨的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI ADVANCED RESEARCH INSTITUTE, CHINESE ACAD Free format text: FORMER OWNER: SHANGHAI ZHONGKE INSTITUTE FOR ADVANCED STUDY Effective date: 20131023 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20131023 Address after: 200031 No. 320, Yueyang Road, Shanghai Applicant after: Shanghai Institute of life Sciences, Chinese Academy of Sciences Applicant after: Shanghai Advanced Research Institute, Chinese Academy of Sciences Address before: 200031 No. 320, Yueyang Road, Shanghai Applicant before: Shanghai Institute of life Sciences, Chinese Academy of Sciences Applicant before: Shanghai Zhongke Institute for Advanced Study |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160824 Address after: 201203 Shanghai city Pudong New Area Hartcourt Road No. 99 Patentee after: Shanghai Advanced Research Institute, Chinese Academy of Sciences Address before: 200031 No. 320, Yueyang Road, Shanghai Patentee before: Shanghai Institute of life Sciences, Chinese Academy of Sciences Patentee before: Shanghai Advanced Research Institute, Chinese Academy of Sciences |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131120 Termination date: 20200702 |